Skip to main content

All Articles

IMpower150 Study: Atezolizumab in Combination with Bevacizumab and Chemotherapy in EGFR-Mutated NSCLC
Lung Cancer
2020 Year in Review - Non–Small-Cell Lung Cancer
Researchers reported improved overall survival in patients with nonsquamous non–small-cell lung cancer with EGFR mutations. Read More ›
Tarloxotinib in Patients with Advanced NSCLC Harboring an EGFR Exon 20 Insertion or HER2-Activating Mutation
Lung Cancer
2020 Year in Review - Non–Small-Cell Lung Cancer
Tarloxotinib treatment was well tolerated and sizeable percentages of patients in both study cohorts achieved either partial response or stable disease. Read More ›
ADAURA Trial: Osimertinib in Resected EGFR-Mutated NSCLC
Lung Cancer
2020 Year in Review - Non–Small-Cell Lung Cancer
Osimertinib shows promise as an adjuvant treatment for patients with stage IB to IIIA EGFR mutation–positive NSCLC. Read More ›
Upfront Local Radiation Therapy and First-Line TKI versus TKI Alone in Previously Untreated EGFR-Mutated Oligometastatic NSCLC
Lung Cancer
2020 Year in Review - Non–Small-Cell Lung Cancer
Improved progression-free survival and overall survival in patients who received upfront stereotactic radiotherapy and TKI treatment should prompt additional study. Read More ›
Selpercatinib Shows Antitumor Intracranial Activity in RET Fusion–Positive Patients with NSCLC and CNS Metastases
Lung Cancer
2020 Year in Review - Non–Small-Cell Lung Cancer
Previously untreated patients and those who had received prior intracranial radiotherapy responded to selpercatinib treatment. Read More ›
Sym015 Showed Similar Response Rate to MET TKI in Patients with METAmp/Ex14Δ NSCLC
Lung Cancer
2020 Year in Review - Non–Small-Cell Lung Cancer
Treatment was well tolerated and also associated with delayed progression in previously treated patients with NSCLC and METAmp/Ex14Δ. Read More ›
Poziotinib Shows Promise for Treating Patients with NSCLC and EGFR or HER2 Exon 20 Insertion Mutations
Lung Cancer
2020 Year in Review - Non–Small-Cell Lung Cancer
This study reports on the ZENITH20-2 cohort of previously treated patients with advanced NSCLC and an HER2 exon 20 insertion mutation. Read More ›
Savolitinib Shows Potential for Patients with NSCLC and MET Exon 14 Skipping Mutations
Lung Cancer
2020 Year in Review - Non–Small-Cell Lung Cancer
Savolitinib had promising antitumor activity in patients with METex14+ NSCLC and showed acceptable tolerability. Read More ›

Page 122 of 298